Optimizing Recovery in Abdominoplasty
- Conditions
- Postoperative Pain
- Interventions
- Other: Standard of care
- Registration Number
- NCT04254692
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
The overall purpose of this study is to evaluate the analgesic efficacy of liposomal bupivacaine in optimizing pain control, minimizing the risk of postoperative nausea and vomiting (PONV), and improving recovery after abdominoplasty. This will be done by comparing intraoperative abdominal wall and incisional injection of bupivacaine to bupivacaine plus liposomal bupivacaine in 46 participants 18 years and older undergoing elective abdominoplasty. This will be studied using pain assessments, validated surveys, medication logs and review of medical records.
- Detailed Description
Postoperative pain, nausea, and vomiting can be frustrating sequelae of elective surgery. Poorly managed postoperative pain can lead to increased opioid use, increased postoperative nausea and vomiting (PONV), delayed return to work and usual activities, unplanned hospital admissions, surgical complications, and patient dissatisfaction. In light of the growing opioid epidemic in the United States, any intervention that potentially minimizes opioid use may have meaningful individual and societal impact. Despite the use of multiple techniques for managing postoperative pain in abdominoplasty patients, pain control continues to be a challenge for this patient population.
One technique commonly employed to improve pain control is the use of abdominal wall and incisional injection of local anesthetic agents to block the sensory nerves supplying the anterior abdominal wall and abdominal incisions in order to decrease sensation and pain in the abdomen in the setting of abdominoplasty surgery. Local anesthetic often used in this procedure is bupivacaine (Marcaine) ± epinephrine. However, in 2012, a liposomal bupivacaine suspension (Exparel; Pacira BioSciences, Inc, San Diego, California) was introduced as a longer-acting local anesthetic used for management of postoperative pain. At the University of Wisconsin, patients undergoing abdominoplasty routinely receive intraoperative injection of local anesthetic to the abdominal wall and abdominal incisions, using bupivacaine as the local anesthetic, along with standard multimodal perioperative pain management including cool compresses, non-steroidal anti-inflammatories (NSAIDs), acetaminophen, and opioids.
The overall purpose of this study is to evaluate the analgesic efficacy of liposomal bupivacaine in optimizing pain control, minimizing the risk of PONV, and improving recovery after abdominoplasty. This will be done by comparing intraoperative abdominal wall and incisional injection of bupivacaine to bupivacaine plus liposomal bupivacaine in patients undergoing abdominoplasty. This will be studied using pain assessments, validated surveys, medication logs and review of medical records.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
- Medically cleared to undergo elective surgery (including associated anesthesia) at UW Madison Surgery Center (MSC).
- Pregnant or breast-feeding women
- Incarcerated women or men
- Individuals unable to give consent due to another condition such as impaired decision-making capacity.
- Men or women who take opioid pain medications on a regular basis prior to surgery
- Men or women with a history of opioid abuse and/or dependence
- Participants with a history of bleeding disorders precluding safe abdominoplasty
- Participants on anticoagulation therapy who have not held their anticoagulation as recommended by their surgeon or anesthesiologist
- Participants not medically cleared for surgery at Madison Surgery Center. This would include participants with sepsis/bacteremia, significant valvular disorders or heart conditions.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Liposomal Bupivacaine Liposomal bupivacaine Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall. Bupivacaine Standard of care Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
- Primary Outcome Measures
Name Time Method Opioid Use at 24 Hours 24 hours postoperatively Amount of opioids used postoperatively, measured in morphine equivalents
- Secondary Outcome Measures
Name Time Method Number of Participants With Postoperative Complications 1 week postoperatively Pain Score 1 Week Postop 1 week postoperatively The pain survey is scored on a 0-10 scale where 0 is no pain and 10 is the worst possible pain.
Antiemetic Use 1 Week 1 week postoperatively total antiemetic used
Quality of Recovery-40 (QOR-40) Score 24 hours postoperatively The QOR-40 is a 40 item survey about the quality of recovery with a total possible range of scores from 40 to 200 where the higher the score the higher quality the recovery.
Pain Score Postoperative Day 1 (POD 1) 24 hours postoperatively The pain survey is scored on a 0-10 scale where 0 is no pain and 10 is the worst possible pain.
Antiemetic Use POD 1 24 hours postoperatively total antiemetic used
Opioid Use at 1 Week 1 week postoperatively total opioid used, measure in morphine equivalents
Number of Participants With Postoperative Nausea and Vomiting 24 hours postoperatively
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
University of Wisconsin Madison Surgery Center
🇺🇸Madison, Wisconsin, United States
University of Wisconsin Madison
🇺🇸Madison, Wisconsin, United States